Pharmacokinetics of Imeglimin in Subjects with Moderate Hepatic Impairment

被引：0
|
作者：
Clémence Chevalier
Julie Dubourg
Sébastien Bolze
Pascale Fouqueray
机构：
[1] Poxel SA,
来源：
Clinical Pharmacokinetics | 2021年 / 60卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：485 / 490
页数：5
相关论文
共 50 条
  • [1] Pharmacokinetics of Imeglimin in Subjects with Moderate Hepatic Impairment
    Chevalier, Clemence
    Dubourg, Julie
    Bolze, Sebastien
    Fouqueray, Pascale
    [J]. CLINICAL PHARMACOKINETICS, 2021, 60 (04) : 485 - 490
  • [2] Pharmacokinetics of Maribavir in Subjects with Moderate Hepatic Impairment
    Song, I. H.
    Ilic, K.
    Wu, J.
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2020, 20 : 792 - 792
  • [3] Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment
    Schnell, David
    Buschke, Susanne
    Fuchs, Holger
    Gansser, Dietmar
    Goeldner, Rainer-Georg
    Uttenreuther-Fischer, Martina
    Stopfer, Peter
    Wind, Sven
    Petersen-Sylla, Marc
    Halabi, Atef
    Koenen, Ruediger
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 74 (02) : 267 - 275
  • [4] Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment
    David Schnell
    Susanne Buschke
    Holger Fuchs
    Dietmar Gansser
    Rainer-Georg Goeldner
    Martina Uttenreuther-Fischer
    Peter Stopfer
    Sven Wind
    Marc Petersen-Sylla
    Atef Halabi
    Rüdiger Koenen
    [J]. Cancer Chemotherapy and Pharmacology, 2014, 74 : 267 - 275
  • [5] Apixaban Pharmacokinetics and Pharmacodynamics in Subjects with Mild or Moderate Hepatic Impairment
    Frost, Charles E.
    Ly, Van
    Garonzik, Samira M.
    [J]. DRUGS IN R&D, 2021, 21 (04) : 375 - 384
  • [6] Pharmacokinetics of sirolimus (rapamycin) in subjects with mild to moderate hepatic impairment
    Zimmerman, JJ
    Lasseter, KC
    Lim, HK
    Harper, D
    Dilzer, SC
    Parker, V
    Matschke, K
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 45 (12): : 1368 - 1372
  • [7] Apixaban Pharmacokinetics and Pharmacodynamics in Subjects with Mild or Moderate Hepatic Impairment
    Charles E. Frost
    Van Ly
    Samira M. Garonzik
    [J]. Drugs in R&D, 2021, 21 : 375 - 384
  • [8] PHARMACOKINETICS OF TMC435 IN SUBJECTS WITH MODERATE HEPATIC IMPAIRMENT
    Sekar, V.
    Simion, A.
    Peeters, M.
    Spittaels, K.
    Lawitz, E.
    Marbury, T. C.
    De Smedt, G.
    [J]. JOURNAL OF HEPATOLOGY, 2011, 54 : S193 - S193
  • [9] The pharmacokinetics and safety of idelalisib in subjects with moderate or severe hepatic impairment
    Jin, Feng
    Robeson, Michelle
    Zhou, Huafeng
    Hisoire, Grace
    Ramanathan, Srini
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2015, 55 (08): : 944 - 952
  • [10] The pharmacokinetics of dalbavancin in subjects with mild, moderate, or severe hepatic impairment
    J Dowell
    E Seltzer
    M Buckwalter
    T Marbury
    D Simoneau
    E Boudry
    [J]. Critical Care, 12 (Suppl 2):
12345